Terns Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Terns Pharmaceuticals, Inc.

12 min	Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting TERN GlobeNewswire
Oct-21	Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity TERN GlobeNewswire
Oct-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) TERN GlobeNewswire
Aug-21	Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 TERN GlobeNewswire
Aug-05	Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates TERN GlobeNewswire
Aug-04	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) TERN GlobeNewswire
Jun-23	Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions TERN GlobeNewswire
May-29	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences TERN GlobeNewswire
May-14	Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 TERN GlobeNewswire
May-08	Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates TERN GlobeNewswire
May-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) TERN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.